Search
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084] … [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Mixtures: ROPITAL 18/2 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL , 120 KAPSÜL, ROPITAL 18/2 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER , 60 DOZCategories: Heterocyclic Compounds, 2-RingDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and
Products: DUPİXENT 200 mg/ 1,14ml ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, DUPİXENT 300 MG/2ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETFesoterodine
go.drugbank.com/drugs/DB06702ApprovedFesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Products: FOSETAZ 4 MG UZATILMIŞ SALIMLI FİLM KAPLI TABLET, 28 ADET, FOSETAZ 8 MG UZATILMIŞ SALIMLI FİLM KAPLI TABLET, 28 ADETQuinidine barbiturate
go.drugbank.com/drugs/DB01346ApprovedThe administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittentl...
Products: NATISEDINE 100 MG TABLET, 20 ADETDequalinium
go.drugbank.com/drugs/DB04209ApprovedDequalinium is an antibacterial agent with multi-targeted actions. It also possesses antifungal, antiparasitic, antiviral, anticancer, and neuroprotective properties. It is a quaternary ammonium compound, as it consists of an amphipathic...
Categories: Heterocyclic Compounds, 2-RingSynonyms: 1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichlorideRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalIn contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells.
Categories: Vascular Endothelial Growth Factor Receptor 2 AntagonistProducts: CYRAMZA 500 MG/50 ML İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇEREN FLAKON, 1 ADET, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 2 ADETPotassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigationalPotassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered...
Mixtures: GALVİKS ADVANCE 1000 MG+200 MG/10 ML ORAL SÜSPANSİYON, 200 ML, PRONAT ADVANCE 100 MG+20 MG ORAL SÜSPANSİYONProducts: Effer-K 10 mEq Unflavored, Effer-K 20 mEq UnflavoredAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a ...
Products: PRALUENT 150 MG/ML SC ENJEKSIYONLUK ÇÖZELTI IÇEREN KULLANIMA HAZIR KALEM,2 ADET, PRALUENT 150 MG/ML SC ENJEKSIYONLUK ÇÖZELTI IÇEREN KULLANIMA HAZIR ENJEKTÖR,2 ADETBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigationalthe use of baricitinib for the treatment of COVID-19 in May 2022. … [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020,[L22619] the FDA fully approved
Categories: Heterocyclic Compounds, 1-Ring, Experimental Unapproved Treatments for COVID-19Products: UNAMİTY 2 MG FİLM KAPLI TABLET, 14 ADET, UNAMİTY 4 MG FİLM KAPLI TABLET, 14 ADETSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and
Products: SIMKELMA 10 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 28 ADET, SIMKELMA 10 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 11 ADET